The PRS developed for predicting ER-negative breast cancer showed the strongest association with breast cancer risk for BRCA1 carriers, while for BRCA2 carriers the PRS developed for predicting overall breast cancer risk performed best. The gene discussed is BRCA2; the disease is breast carcinoma.